A role of estrogen/ERα signaling in BRCA1-associated tissue-specific tumor formation

Oncogene

Volumn 26, Issue 51, 2007, Pages 7204-7212

  Li, W ^a   Xiao, C ^a   Vonderhaar, B K ^b   Deng, C X ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BRCA1; Cyclin D1; ER ; ERK1 2; Mammary tumors

Indexed keywords

BRCA1 PROTEIN; CYCLIN D1; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; BREAST TUMOR; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAMMARY GLAND; MOLECULAR BIOLOGY; MOUSE; MUTANT; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; TISSUE SPECIFICITY; TUMOR GROWTH; ANIMAL; CELL LINE; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BRCA1 PROTEIN; CELL LINE; CYCLIN D1; ESTROGENS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 36048959828     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210527     Document Type: Article

References (34)

1. Alberg AJ, Lam AP, Helzlsouer KJ. (1999). Epidemiology, prevention, and early detection of breast cancer. Curr Opin Oncol 11: 435-441.
2. Bachelier R, Li C, Qiao W, Furth PA, Lubet RA, Deng CX. (2005). Effects of bilateral oophorectomy on mammary tumor formation in breast cancer associated gene 1 (Brca1) mutant mice. Oncol Rep 14: 1117-1120.
3. Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX. (2001). Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20: 7514-7523.
4. Calderon-Margalit R, Paltiel O. (2004). Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 112: 357-364.
5. Chodankar R, Kwang S, Sangiorgi F, Hong H, Yen HY, Deng C et al. (2005). Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 15: 561-565.
6. Clarke RB, Howell A, Potten CS, Anderson E. (1997). Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57: 4987-4991.
7. Deng CX, Wang RH. (2003). Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet 12: R113-R123.
8. Deng CX, Xu X. (2004). Generation and analysis of Brca1 conditional knockout mice. Methods Mol Biol 280: 185-200.
9. Deng CX. (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response, and cancer evolution. Nucleic Acids Res 34: 1416-1426.
10. Eisinger F, Jacquemier J, Nogues C, Birnbaum D, Sobol H. (1999). Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 85: 2291-2295.
11. Elledge SJ, Amon A. (2002). The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell 1: 129-132.
12. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR et al. (1999). BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354-1356.
13. Gadducci A, Biglia N, Sismondi P, Genazzani AR. (2005). Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol 20: 343-360.
14. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A et al. (2005). Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24: 8343-8348.
15. Huo Z, Giger ML, Olopade OI, Wolverton DE, Weber BL, Metz CE et al. (2002). Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology 225: 519-526.
16. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V et al. (1997). Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33: 362-371.
17. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN et al. (1997). Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435-441.
18. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al. (2002). Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609-1615.
19. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS et al. (1996). Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 51: 159-186; discussion 186-188.
20. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. (1995). Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 9: 2712-2722.
21. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E et al. (1996). Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15: 1292-1300.
22. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71.
23. Monteiro AN. (2003). BRCA1: the enigma of tissue-specific tumor development. Trends Genet 19: 312-315.
24. Prall OW, Rogan EM, Sutherland RL. (1998). Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol 65: 169-174.
25. Russo IH, Russo J. (1998). Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49-61.
26. Russo J, Ao X, Grill C, Russo IH. (1999). Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53: 217-227.
27. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH et al. (2002). The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256.
28. Trauernicht AM, Boyer TG. (2003). BRCA1 and estrogen signaling in breast cancer. Breast Dis 18: 11-20.
29. Turner JM, Aprelikova O, Xu X, Wang R, Kim S, Chandramouli GV et al. (2004). BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr Biol 14: 2135-2142.
30. Venkitaraman AR. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
31. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA et al. (2001). Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28: 266-271.
32. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T et al. (1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation [see comments]. Nat Genet 22: 37-43.
33. Zhang J, Powell SN. (2005). The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 3: 531-539.
34. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. (2001). BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 98: 9587-9592.